Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/53744
Title: Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC
Authors: Wan Ling Tan
Kevin L.M. Chua
Chia Chi Lin
Victor H.F. Lee
Lye Mun Tho
Anthony W. Chan
Gwo Fuang Ho
Thanyanan Reungwetwattana
James C. Yang
Dong Wan Kim
Ross A. Soo
Yong Chan Ahn
Hiroshi Onishi
Myung Ju Ahn
Tony S.K. Mok
Daniel S.W. Tan
Fan Yang
Peking University People's Hospital
National Taiwan University Hospital
National Cancer Centre, Singapore
National University Hospital, Singapore
Seoul National University Hospital
SungKyunKwan University, School of Medicine
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
University of Malaya Medical Centre
University of Yamanashi
The University of Hong Kong
Chinese University of Hong Kong
Beacon Hospital
Keywords: Medicine
Issue Date: 1-Mar-2020
Citation: Journal of Thoracic Oncology. Vol.15, No.3 (2020), 324-343
Abstract: © 2019 Stage III NSCLC represents a heterogeneous disease for which optimal treatment continues to pose a clinical challenge. Recent changes in the American Joint Commission on Cancer staging to the eighth edition has led to a shift in TNM stage grouping and redefined the subcategories (IIIA–C) in stage III NSCLC for better prognostication. Although concurrent chemoradiotherapy has remained standard-of-care for stage III NSCLC for almost 2 decades, contemporary considerations include the impact of different molecular subsets of NSCLC, and the roles of tyrosine kinase inhibitors post-definitive therapy and of immune checkpoint inhibitors following chemoradiotherapy. With rapid evolution of diagnostic algorithms and expanding treatment options, the need for interdisciplinary input involving multiple specialists (medical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists and thoracic surgeons) has become increasingly important. The unique demographics of Asian NSCLC pose further challenges when applying clinical trial data into clinical practice. This includes differences in smoking rates, prevalence of oncogenic driver mutations, and access to health care resources including molecular testing, prompting the need for critical review of existing data and identification of current gaps. In this expert consensus statement by the Asian Thoracic Oncology Research Group, an interdisciplinary group of experts representing Hong Kong, Korea, Japan, Taiwan, Singapore, Thailand, Malaysia, and Mainland China was convened. Standard clinical practices for stage III NSCLC across different Asian countries were discussed from initial diagnosis and staging through to multi-modality approaches including surgery, chemotherapy, radiation, targeted therapies, and immunotherapy.
URI: http://repository.li.mahidol.ac.th/dspace/handle/123456789/53744
metadata.dc.identifier.url: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85080091130&origin=inward
ISSN: 15561380
15560864
Appears in Collections:Scopus 2020

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.